Acute Lymphoblastic Leukemia (ALL)

The most common early signs include persistent tiredness, pallor, repeated infections, easy bruising or unusual bleeding, and bone or joint pain. These symptoms reflect the impact of leukemia cells on normal blood production and can develop over days to weeks — often initially mistaken for other illnesses. A complete blood count (CBC) is the first investigation if ALL is suspected.

Diagnosis requires a bone marrow aspiration and biopsy combined with immunophenotyping by flow cytometry, conventional cytogenetics, FISH for key translocations, and molecular testing including PCR for gene fusions such as BCR-ABL1. Next-generation sequencing (NGS) is increasingly standard at diagnosis. A complete workup including lumbar puncture for CNS assessment is required before treatment begins.

Yes — molecular and genetic testing is not optional in ALL. It is essential. The molecular subtype defines risk group, determines whether targeted therapy such as a TKI is needed, guides transplant decisions, and identifies which novel therapies may be applicable. Comprehensive testing should be performed at diagnosis and reconsidered at relapse, as the molecular landscape can change.

Philadelphia chromosome-positive ALL (Ph+ ALL) is defined by the BCR-ABL1 gene fusion. It was historically associated with very poor prognosis. Treatment now combines standard ALL chemotherapy with tyrosine kinase inhibitors (TKIs) such as dasatinib or ponatinib, which specifically block the BCR-ABL1 oncoprotein. Allogeneic stem cell transplantation is frequently recommended in eligible adults with Ph+ ALL. Outcomes have improved substantially with TKI-based approaches.

CAR-T therapy uses a patient's own T cells, modified in a laboratory to recognize and kill CD19-expressing leukemia cells. In B-ALL, tisagenlecleucel (Kymriah) has achieved deep remissions in patients with relapsed or refractory disease and is approved in several countries for pediatric and young adult patients. Access varies by geography and center. Several specialist centers in China offer CAR-T for B-ALL, including domestically developed products. CancerFax can help explore CAR-T eligibility and access.

Minimal Residual Disease (MRD) refers to small numbers of leukemia cells remaining in the body after treatment, detected by sensitive flow cytometry or PCR methods. MRD status after induction therapy is one of the strongest independent predictors of outcome in ALL. MRD positivity signals a need to intensify treatment or consider transplantation; achieving MRD negativity is a primary therapeutic goal associated with better long-term outcomes.

A second opinion is appropriate when ALL is a rare or high-risk molecular subtype, the initial diagnostic workup appears incomplete, MRD remains positive after induction, a transplant decision is being considered, or the disease has relapsed or is not responding to treatment. A second opinion from a specialist hematology center can provide important clinical and molecular perspective that changes management.

Yes. Clinical trials are actively evaluating new CAR-T targets, bispecific antibodies, frontline incorporation of immunotherapy agents, targeted therapy for Ph-like ALL, and MRD-guided treatment de-escalation or escalation strategies. Patients with relapsed, refractory, or high-risk ALL should discuss trial eligibility with their treating team. Specialist centers in China and internationally also have active ALL trial programs.

ALL is the most common cancer in children, accounting for approximately 25% of all pediatric cancers, with a peak incidence between ages 2 and 5. It also occurs in adults, with a second incidence peak after age 50. The disease behaves differently and requires different treatment approaches depending on age: pediatric outcomes are generally more favorable, while adult ALL — especially in older patients — is more challenging to treat.

Yes. CancerFax can review medical reports and molecular workup, coordinate second opinions with specialist hematologists, help identify appropriate treatment centers — including those offering CAR-T, blinatumomab, inotuzumab, and clinical trials — and support coordination for patients exploring treatment in China or internationally. Contact CancerFax to discuss your specific diagnosis and situation.